Trial intelligence / Profile preview

PREVUS: Intensive BP Control in Coronary Artery Disease

NCT01230216Phase 4

Key facts

Status: Terminated
Start: Dec 2010
Primary completion: Mar 2015
Countries: 1
Modality: Small Molecules

Drugs: losartan
Conditions: hypertension (HTN)

Overview

Phase 4, randomised, open-label trial of losartan in hypertension (HTN) (2 arms). Primary endpoint: Change of percent atheroma volume at 1.5 years. Started Dec 2010; status: terminated.

Design

2 arms

Study design: RandomizedOpen-label

Intensive BP Control
Systolic BP < 120 mmHg using losartan
Standard BP Control
Systolic BP < 140 mmHg using losartan

Endpoints

Primary

Change of percent atheroma volume1.5 years

Secondary

All cause death1.5 years
Cardiac death1.5 years
Cardiovascular death1.5 years
Myocardial infarction1.5 years
Stroke1.5 years
Target-lesion revascularization1.5 years
Any coronary revascularization1.5 years
Hospitalization due to angina pectoris1.5 years

Beyond the preview

Go deeper on NCT01230216.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01230216.